Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease

Lysosomal acid lipase (LAL), encoded by the gene LIPA, is the sole neutral lipid hydrolase in lysosomes, responsible for cleavage of cholesteryl esters and triglycerides into their component parts. Inherited forms of complete (Wolman Disease, WD) or partial LAL deficiency (cholesteryl ester storage...

Full description

Bibliographic Details
Main Authors: Katrina J. Besler, Valentin Blanchard, Gordon A. Francis
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Genetics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.1013266/full
_version_ 1811183533743407104
author Katrina J. Besler
Valentin Blanchard
Gordon A. Francis
author_facet Katrina J. Besler
Valentin Blanchard
Gordon A. Francis
author_sort Katrina J. Besler
collection DOAJ
description Lysosomal acid lipase (LAL), encoded by the gene LIPA, is the sole neutral lipid hydrolase in lysosomes, responsible for cleavage of cholesteryl esters and triglycerides into their component parts. Inherited forms of complete (Wolman Disease, WD) or partial LAL deficiency (cholesteryl ester storage disease, CESD) are fortunately rare. Recently, LAL has been identified as a cardiovascular risk gene in genome-wide association studies, though the directionality of risk conferred remains controversial. It has also been proposed that the low expression and activity of LAL in arterial smooth muscle cells (SMCs) that occurs inherently in nature is a likely determinant of the propensity of SMCs to form the majority of foam cells in atherosclerotic plaque. LAL also likely plays a potential role in fatty liver disease. This review highlights the nature of LAL gene mutations in WD and CESD, the association of LAL with prediction of cardiovascular risk from genome-wide association studies, the importance of relative LAL deficiency in SMC foam cells, and the need to further interrogate the pathophysiological impact and cell type-specific role of enhancing LAL activity as a novel treatment strategy to reduce the development and induce the regression of ischemic cardiovascular disease and fatty liver.
first_indexed 2024-04-11T09:48:31Z
format Article
id doaj.art-3e93a95674164789ab817cfb0bcc9cee
institution Directory Open Access Journal
issn 1664-8021
language English
last_indexed 2024-04-11T09:48:31Z
publishDate 2022-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Genetics
spelling doaj.art-3e93a95674164789ab817cfb0bcc9cee2022-12-22T04:30:55ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-09-011310.3389/fgene.2022.10132661013266Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver diseaseKatrina J. BeslerValentin BlanchardGordon A. FrancisLysosomal acid lipase (LAL), encoded by the gene LIPA, is the sole neutral lipid hydrolase in lysosomes, responsible for cleavage of cholesteryl esters and triglycerides into their component parts. Inherited forms of complete (Wolman Disease, WD) or partial LAL deficiency (cholesteryl ester storage disease, CESD) are fortunately rare. Recently, LAL has been identified as a cardiovascular risk gene in genome-wide association studies, though the directionality of risk conferred remains controversial. It has also been proposed that the low expression and activity of LAL in arterial smooth muscle cells (SMCs) that occurs inherently in nature is a likely determinant of the propensity of SMCs to form the majority of foam cells in atherosclerotic plaque. LAL also likely plays a potential role in fatty liver disease. This review highlights the nature of LAL gene mutations in WD and CESD, the association of LAL with prediction of cardiovascular risk from genome-wide association studies, the importance of relative LAL deficiency in SMC foam cells, and the need to further interrogate the pathophysiological impact and cell type-specific role of enhancing LAL activity as a novel treatment strategy to reduce the development and induce the regression of ischemic cardiovascular disease and fatty liver.https://www.frontiersin.org/articles/10.3389/fgene.2022.1013266/fulllysosomal acid lipaseLIPAWolman DiseaseCholesteryl Ester Storage DiseaseGWASsmooth muscle cells
spellingShingle Katrina J. Besler
Valentin Blanchard
Gordon A. Francis
Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease
Frontiers in Genetics
lysosomal acid lipase
LIPA
Wolman Disease
Cholesteryl Ester Storage Disease
GWAS
smooth muscle cells
title Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease
title_full Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease
title_fullStr Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease
title_full_unstemmed Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease
title_short Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease
title_sort lysosomal acid lipase deficiency a rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease
topic lysosomal acid lipase
LIPA
Wolman Disease
Cholesteryl Ester Storage Disease
GWAS
smooth muscle cells
url https://www.frontiersin.org/articles/10.3389/fgene.2022.1013266/full
work_keys_str_mv AT katrinajbesler lysosomalacidlipasedeficiencyarareinheriteddyslipidemiabutpotentialubiquitousfactorinthedevelopmentofatherosclerosisandfattyliverdisease
AT valentinblanchard lysosomalacidlipasedeficiencyarareinheriteddyslipidemiabutpotentialubiquitousfactorinthedevelopmentofatherosclerosisandfattyliverdisease
AT gordonafrancis lysosomalacidlipasedeficiencyarareinheriteddyslipidemiabutpotentialubiquitousfactorinthedevelopmentofatherosclerosisandfattyliverdisease